More than 850 million people worldwide are affected by kidney diseases and the impact on those affected and healthcare systems is severely under-recognised.1 Although progress has been made in treatment and management, prevalence is rising and kidney diseases are predicted to become the fifth leading cause of lives lost by 2040.1,2 We want to change this.
For 20 years, we have combined innovation, scientific expertise and commitment to patients to address unmet needs in kidney diseases. Applying our expertise in immunology, we aim to continue delivering meaningful value for those affected, healthcare systems and society.
Our industry-leading pipeline, informed and guided by the needs of patients, spans lupus nephritis, membranous nephropathy, immunoglobulin A nephropathy, atypical haemolytic uraemic syndrome, childhood-onset idiopathic nephrotic syndrome and systemic lupus erythematosus, an autoimmune disease that can lead to lupus nephritis.
References
Jager KJ, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048-1050
Nature Reviews Nephrology. 2024;20:473–485
Hear from Pippa Postins, Global Integrated Strategy Leader, Nephrology & Rheumatology and Michael Oberreiter, Head of Global Access at Roche, about Roche’s ambitious goals for kidney and kidney-related diseases.